Medical Burden of Respiratory Syncytial Virus and Parainfluenza Virus Type 3 Infection Among US Children: Implications for Design of Vaccine Trials

Respiratory syncytial virus (RSV) and parainfluenza virus type 3 (PIV3) are two leading causes of lower respiratory illness (LRI) in infants. Many efforts have been directed to develop vaccines against these two viruses. Licensure of new vaccines includes three phases of clinical trials to evaluate safety, immunogenicity, and efficacy. To design an efficacy trial, age-specific incidence rates of suitable clinical endpoints need to be available. In this review, historical data are summarized to estimate the age-specific rates of acute respiratory illness (ARI), LRI, and hospitalization caused by RSV and PIV3 among US children

[1]  B. Mellen,et al.  Rates of hospitalization for respiratory syncytial virus infection among children in medicaid. , 2000, The Journal of pediatrics.

[2]  W. P. Glezen,et al.  Respiratory disease in group day care. , 1972, Pediatrics.

[3]  Benjamin Schwartz,et al.  Population-based surveillance for hospitalizations associated with respiratory syncytial virus, influenza virus, and parainfluenza viruses among young children. , 2004, Pediatrics.

[4]  R. Holman,et al.  Human parainfluenza virus-associated hospitalizations among children less than five years of age in the United States , 2001, The Pediatric infectious disease journal.

[5]  J. Tam,et al.  Simultaneous Detection, Subgrouping, and Quantitation of Respiratory Syncytial Virus A and B by Real-Time PCR , 2003, Journal of Clinical Microbiology.

[6]  R. Holman,et al.  Bronchiolitis-associated hospitalizations among US children, 1980-1996. , 1999, JAMA.

[7]  J. Sinnott,et al.  Respiratory Syncytial Virus , 1988, Infection Control & Hospital Epidemiology.

[8]  R. Chanock,et al.  Epidemiology of respiratory syncytial virus infection in Washington, D.C. I. Importance of the virus in different respiratory tract disease syndromes and temporal distribution of infection. , 1973, American journal of epidemiology.

[9]  W. Gruber,et al.  Twenty years of outpatient respiratory syncytial virus infection: a framework for vaccine efficacy trials. , 1997, Pediatrics.

[10]  W. P. Glezen,et al.  Risk of primary infection and reinfection with respiratory syncytial virus. , 1986, American journal of diseases of children.

[11]  Kelly J. Henrickson.  Parainfluenza Viruses , 2003, Clinical Microbiology Reviews.

[12]  R. Karron,et al.  Progress in the development of respiratory syncytial virus and parainfluenza virus vaccines. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[13]  R. Karron,et al.  The future of respiratory syncytial virus vaccine development , 2004, The Pediatric infectious disease journal.

[14]  W. P. Glezen,et al.  Morbidity associated with the major respiratory viruses. , 1990, Pediatric annals.

[15]  P. Jewett,et al.  Epidemiology and clinical impact of parainfluenza virus infections in otherwise healthy infants and young children < 5 years old. , 1997, The Journal of infectious diseases.

[16]  W. P. Glezen,et al.  Parainfluenza virus type 3: seasonality and risk of infection and reinfection in young children. , 1984, The Journal of infectious diseases.

[17]  C. Hall,et al.  Parainfluenza viral infections in pediatric outpatients: seasonal patterns and clinical characteristics. , 1994, The Pediatric Infectious Disease Journal.

[18]  L. Taussig,et al.  THE TUCSON CHILDREN'S RESPIRATORY STUDY. II. LOWER RESPIRATORY TRACT ILLNESS IN THE FIRST YEAR OF LIFE , 1989, American journal of epidemiology.

[19]  Benjamin Schwartz,et al.  Superiority of reverse-transcription polymerase chain reaction to conventional viral culture in the diagnosis of acute respiratory tract infections in children. , 2004, The Journal of infectious diseases.